ALNYLAM PHARMACEUTICALS, INC. (ALNY) › Total AssetsALNYLAM PHARMACEUTICALS, INC. (ALNY) — Total AssetsAnnual figures by period end, from SEC filings.2009-12-31: $481.38M2010-12-31: $393.26M2011-12-31: $281.92M2012-12-31: $287.52M2013-12-31: $420.53M2014-12-31: $1.08B2015-12-31: $1.39B2016-12-31: $1.26B2017-12-31: $1.99B2018-12-31: $1.57B2019-12-31: $2.40B2020-12-31: $3.41B2021-12-31: $3.64B2022-12-31: $3.55B2023-12-31: $3.83B2024-12-31: $4.24B2025-12-31: $4.97B$4.97B2009-12-31Total Assets (USD)2025-12-31Period endedTotal AssetsChange YoYSource filing2025-12-31$4.97B+17.1%2026-02-12Balance as of period end2024-12-31$4.24B+10.7%2026-02-12Balance as of period end2023-12-31$3.83B+8.0%2025-02-13Balance as of period end2022-12-31$3.55B-2.7%2024-02-15Balance as of period end2021-12-31$3.64B+6.9%2023-02-23Balance as of period end2020-12-31$3.41B+42.2%2022-02-10Balance as of period end2019-12-31$2.40B+52.1%2021-02-11Balance as of period end2018-12-31$1.57B-21.1%2020-02-13Balance as of period end2017-12-31$1.99B+58.0%2019-02-14Balance as of period end2016-12-31$1.26B-8.9%2018-02-15Balance as of period end2015-12-31$1.39B+28.4%2017-02-15Balance as of period end2014-12-31$1.08B+156.7%2016-02-12Balance as of period end2013-12-31$420.53M+46.3%2015-02-13Balance as of period end2012-12-31$287.52M+2.0%2014-02-20Balance as of period end2011-12-31$281.92M-28.3%2013-02-19Balance as of period end2010-12-31$393.26M-18.3%2012-02-13Balance as of period end2009-12-31$481.38M—2011-02-18Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)